Callos Andrew 4

What Happened

• Andrew Callos, EVP and Chief Commercial Officer of Cytokinetics (CYTK), was granted a mix of restricted stock units (RSUs) and stock options on 2026-03-15. The grants, reported on a Form 4 filed 2026-03-17, consist of 20,646 RSUs, 13,320 RSUs (special supplemental award), 1,665 stock option units (derivative), and 29,480 stock option units (derivative) — a total of 65,111 equity awards. All awards show an acquisition price of $0 (grants/awards, not purchases).

Key Details

• Transaction date: 2026-03-15; Form 4 filed: 2026-03-17 (appears timely).
• Awards and prices:
  • 20,646 RSUs (F1) — $0 acquisition price.
  • 13,320 RSUs (F2, special supplemental award) — $0 acquisition price.
  • 1,665 stock options (F3, derivative) — $0 acquisition price.
  • 29,480 stock options (F4, derivative) — $0 acquisition price.
• Vesting/terms (from filing footnotes):
  • F1 RSUs: convert 1:1 to common stock; vest 40% at year 1, 40% at year 2, 20% at year 3 (subject to continued employment).
  • F2 RSUs: convert 1:1; vest 50% at year 1 and 50% at year 2 (subject to continued employment).
  • F3 & F4 stock options: vest in 48 equal monthly installments (subject to continued employment).
• Shares owned after the transaction: not specified in the summary information provided.
• No 10b5-1 plan, tax withholding, or late-filing flag noted in the provided details.

Context

• These are compensation grants (awards), not open-market purchases or sales. RSUs convert to shares on the stated vesting schedule; stock options are derivative awards that will vest monthly over four years. Such awards are typical executive compensation and do not by themselves indicate a buy or sell decision in the market.